NewAmsterdam Pharma Company N.V. (NAMSW) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Gooimeer 2-35
Naarden, 1411 DC
Netherlands (Kingdom of the)
Phone
31 35 206 2971
Sector
Healthcare
Industry
Biotechnology
Employees
68
First IPO Date
February 10, 2021
| Name | Title | Pay | Year Born |
| Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director | 1.14M | 1956 |
| Juliette Audet | Chief Strategy & Business Officer | 653,039 | 1987 |
| Louise Kooij | Chief Accounting Officer | 695,419 | 1976 |
| Mayur Amrat Somaiya | Chief Financial Officer | 770,393 | 1974 |
| Douglas F. Kling | Chief Operating Officer | 790,051 | 1973 |
| Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director | 808,143 | 1954 |
| Marc Ditmarsch | Chief Development Officer | 0 | 1967 |
| Bob Rambo | Executive Vice President of Marketing | 0 | N/A |
| Chris Deluzio | Executive Vice President of Sales Enterprise Operations | 0 | N/A |
| Matthew Philippe | Executive VP & Head of Investor Relations | 0 | N/A |
| Michael F. Marino | Chief Legal Officer & Corporate Secretary | 0 | 1976 |
| Maryellen McQuade | Chief People Officer | 0 | N/A |
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.